Vanstar Mining Resources Inc (1V8) Quote

Fixed-duration CALQUENCE® (acalabrutinib) plus venetoclax, with or without obinutuzumab, significantly improved progression-free survival in 1st-line chronic lymphocytic leukemia in AMPLIFY Phase III trial

Favorable trend in overall survival was also observed Positive high-level results from an interim analysis of the AMPLIFY Phase III trial showed a fixed duration of AstraZeneca’s CALQUENCE®...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

AstraZeneca’s H1 and Q2 2024 Financial Results

Strong underlying growth supports FY 2024 guidance upgrade, with both Total Revenue and Core EPS now expected to increase by a mid teens percentage at CER1 AstraZeneca: Revenue and EPS summary H1...

U.S. Index Futures Mixed After Tech Sell-Off, Oil Prices Drop on Weak China Demand and Ceasefire Expectations

U.S. index futures are mixed in pre-market trading on Thursday following a sharp tech sector sell-off the previous day. At 5:17 AM, Dow Jones futures (DOWI:DJI) rose 85 points, or 0.21%. S&P...

Earnings Updates: Ford Shares Fall 13% on EPS Miss, Stellantis Down 6%, Viking Therapeutics Up 20%, Unilever Up 5%

Ford Motor (NYSE:F) – The global automaker reported adjusted earnings per share of $0.47 in the second quarter, below the $0.67 expected, impacted by ongoing warranty issues. Revenue...

Voydeya approved in Canada as add-on therapy to ravulizumab or eculizumab for adults with the rare disease PNH who have residual hemolytic anemia due to extravascular hemolysis

Voydeya approved in Canada as add-on therapy to ravulizumab or eculizumab for adults with the rare disease PNH who have residual hemolytic anemia due to extravascular hemolysis Canada...

IMFINZI® (durvalumab) demonstrated statistically significant and clinically meaningful improvement in event-free survival and overall survival for muscle-invasive bladder cancer in NIAGARA Phase III trial

First immunotherapy regimen before and after surgery to extend survival in bladder cancer Positive high-level results from the NIAGARA Phase III trial showed AstraZeneca’s IMFINZI® (durvalumab...

IMFINZI® (durvalumab) plus chemotherapy approved in the US for mismatch repair deficient advanced or recurrent endometrial cancer

Approval based on DUO-E trial results, which showed IMFINZI reduced the risk of disease progression or death by 58% vs. chemotherapy AstraZeneca’s IMFINZI® (durvalumab) in combination with...

CALQUENCE® (acalabrutinib) plus chemoimmunotherapy reduced the risk of disease progression or death by 27% vs. standard of care in patients with untreated mantle cell lymphoma in ECHO Phase III trial

First and only BTK inhibitor to demonstrate favorable overall survival trend vs. standard-of-care chemoimmunotherapy in this setting Positive results from the ECHO Phase III trial showed...